Profile data is unavailable for this security.
About the company
J. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its therapeutic categories include gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives and pharmacovigilance. The Company's lozenges products include center-filled, soft-centered lozenges; center-filled, powder lozenges; herbal lozenges, and medicated lozenges. The Company offers a complete range of contrast media products including X-ray, MRI, and ultrasound in India as well as internationally. The Company produces a wide range of dosage forms, such as tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges and sips. Its brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA and Sporlac G, among others.
- Revenue in INR (TTM)33.85bn
- Net income in INR5.14bn
- Incorporated1976
- Employees5.10k
- LocationJ B Chemicals and Pharmaceuticals LtdCnergy It Park, Appa Saheb Marathe MargMUMBAI 400025IndiaIND
- Phone+91 2 224395200
- Fax+91 2 224395500
- Websitehttps://jbpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 163.98bn | 1.17k | 44.19 | -- | 39.04 | 14.04 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
| Natco Pharma Ltd. | 38.28bn | 12.78bn | 178.23bn | 3.98k | 14.05 | -- | 12.29 | 4.66 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
| Piramal Enterprises Ltd | 80.27bn | -16.84bn | 184.93bn | 12.22k | -- | 0.6963 | -- | 2.30 | -76.51 | -76.51 | 345.53 | 1,187.94 | 0.0965 | -- | 497.33 | -- | -2.02 | 2.57 | -2.05 | 3.16 | 45.17 | 81.98 | -20.97 | 21.59 | -- | -0.0035 | 0.6686 | 26.39 | -3.80 | -7.55 | -116.89 | -- | 12.91 | -18.22 |
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 188.68bn | 14.59k | 30.63 | 3.92 | 21.21 | 3.03 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | -- | 9.77 | 10.82 | 12.94 | 14.38 | 72.46 | 67.67 | 9.90 | 12.58 | 0.9863 | 11.76 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Piramal Pharma Ltd | 81.71bn | 178.20m | 197.50bn | 6.30k | 2,497.50 | 2.51 | 26.04 | 2.42 | 0.06 | 0.06 | 65.09 | 59.80 | 0.5478 | 1.53 | 4.15 | -- | 0.1195 | -- | 0.1648 | -- | 63.85 | -- | 0.2181 | -- | 0.7527 | 6.74 | 0.3732 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Pfizer Ltd | 22.19bn | 5.02bn | 201.32bn | 1.70k | 40.09 | -- | 34.89 | 9.07 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
| Sanofi India Ltd | 28.47bn | 5.49bn | 203.87bn | 2.17k | 37.13 | -- | 34.61 | 7.16 | 238.42 | 238.42 | 1,236.19 | -- | -- | -- | -- | 13,095,680.00 | -- | 22.42 | -- | 30.21 | 57.68 | 55.52 | 19.29 | 21.03 | -- | 442.82 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Laurus Labs Ltd | 50.41bn | 1.61bn | 237.23bn | 5.75k | 148.20 | 5.77 | 42.91 | 4.71 | 2.97 | 2.97 | 93.27 | 76.27 | 0.6282 | 1.38 | 3.11 | -- | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 49.35 | 3.34 | 12.83 | 0.6393 | 2.15 | 0.3851 | -- | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Syngene International Ltd | 34.89bn | 5.10bn | 277.23bn | 6.85k | 54.48 | 6.50 | 29.62 | 7.95 | 12.68 | 12.68 | 86.73 | 106.24 | 0.5823 | 3.26 | 7.19 | -- | 8.51 | 8.62 | 10.57 | 11.43 | 73.34 | 71.65 | 14.62 | 16.22 | 1.50 | 6.26 | 0.1154 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| J B Chemicals and Pharmaceuticals Ltd | 33.85bn | 5.14bn | 283.23bn | 5.10k | 55.92 | -- | 44.02 | 8.37 | 32.63 | 32.63 | 214.87 | -- | -- | -- | -- | 6,643,323.00 | -- | 15.37 | -- | 18.18 | 65.83 | 60.20 | 15.19 | 15.49 | -- | 15.00 | -- | 31.73 | 29.91 | 17.36 | 6.35 | 24.26 | 83.84 | 54.75 |
| Glenmark Pharmaceuticals Ltd | 117.51bn | -12.31bn | 287.70bn | 15.56k | -- | -- | -- | 2.45 | -43.61 | -25.22 | 416.16 | -- | -- | -- | -- | 7,553,779.00 | -- | 4.65 | -- | 6.46 | 61.08 | 60.78 | -9.72 | 6.46 | -- | 1.10 | -- | 10.17 | -5.86 | 4.94 | -118.02 | -- | -10.27 | 4.56 |
| Gland Pharma Ltd | 49.12bn | 6.59bn | 295.04bn | 4.59k | 44.80 | -- | 31.11 | 6.01 | 39.98 | 39.98 | 298.11 | -- | -- | -- | -- | 10,713,810.00 | -- | 15.16 | -- | 16.69 | 60.54 | 53.97 | 13.41 | 26.07 | -- | 46.26 | -- | 0.00 | -17.64 | 17.43 | -35.54 | 19.46 | 21.24 | -- |
| Ajanta Pharma Ltd | 42.09bn | 8.16bn | 299.81bn | 7.71k | 36.75 | 8.40 | 31.51 | 7.12 | 64.79 | 64.79 | 334.10 | 283.32 | 0.9034 | 1.30 | 3.65 | -- | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.51 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 15.18 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 71.86bn | 5.64bn | 330.25bn | 16.17k | 58.51 | -- | 35.28 | 4.60 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
| Biocon Ltd | 147.56bn | 10.23bn | 366.04bn | 3.41k | 35.81 | 1.86 | 12.77 | 2.48 | 8.54 | 8.54 | 123.32 | 164.78 | 0.273 | 1.07 | 3.01 | -- | 2.40 | 3.20 | 3.50 | 4.48 | 66.81 | 63.27 | 8.80 | 9.37 | 0.6664 | 1.63 | 0.3917 | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| GlaxoSmithKline Pharmaceuticals Limited | 34.54bn | 5.90bn | 387.43bn | 3.68k | 65.66 | 21.79 | 58.73 | 11.22 | 34.83 | 34.83 | 203.92 | 104.93 | 1.00 | 2.71 | 16.67 | -- | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 56.53 | 17.08 | 12.25 | 1.49 | 466.12 | 0.0104 | -- | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | -- |
Data as of May 18 2024. Currency figures normalised to J B Chemicals and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
16.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Apr 2024 | 4.74m | 3.05% |
| Axis Asset Management Co. Ltd.as of 30 Apr 2024 | 4.18m | 2.69% |
| Abrdn Asia Ltd.as of 16 May 2024 | 2.92m | 1.88% |
| The Vanguard Group, Inc.as of 09 May 2024 | 2.66m | 1.71% |
| Norges Bank Investment Managementas of 30 Jun 2023 | 2.47m | 1.59% |
| Invesco Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 1.81m | 1.17% |
| Canara Robeco Asset Management Co. Ltd.as of 15 May 2024 | 1.78m | 1.15% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Apr 2024 | 1.76m | 1.13% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 1.45m | 0.93% |
| Edelweiss Asset Management Ltd.as of 30 Apr 2024 | 1.31m | 0.84% |
More ▼
Data from 31 Dec 2023 - 16 May 2024Source: FactSet Research Systems Inc.
